Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin

Core One Labs Inc. (CSE: COOL | OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) announces that it has initiated rollout of its commercial sales strategy for its proprietary biosynthetic API psilocybin product.

The company’s commercial sales strategy is a roadmap geared to securing dependable, long-term revenues for the company through the acquisition and retention of new customers, while also focusing on the establishment of key opportunities and relationships that will drive value creation for the company, as well as its shareholder base.

The company’s commercial sales representatives have initiated contact with several pharmaceutical companies, as well as larger publicly traded psychedelic companies requiring psilocybin for studies and drug trials or that have shown interest in the psychedelic research space. The company’s sales representatives have also reached out to numerous psychedelics based medical clinics, organizations conducting psychedelic research initiatives, as well as medical professionals focused on the authorized treatment of patients using psychedelics.

With demand for psychedelic-based therapies and medicines in Canada and around the globe increasing significantly, Core One strives to become the pharmaceutical grade psilocybin supplier of choice for users across the medical psychedelics’ spectrum.

Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.

The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100% owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other 100% owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics the Company intends to integrate a roll out of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.